Median OS was 19.7 months and 19.3 months in patients with HER2/neu+ and HER2/neu− ALL, respectively, and did not differ significantly (p = 0.88, hazard ratio 0.916) (Fig. 1). This evidence concerns the gene ERBB2 and acute lymphoblastic leukemia.